PHASE I STUDY TO EVALUATE THE SAFETY OF CELLULAR ADOPTIVE IMMUNOTHERAPY, CD4+

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The safety, survival and anti-tumor effect of infusions of CD4+ T cells are evaluated in this study. CD4 + T cells produce their own growth factors and may survive for prolonged periods after infusion. This is a dose escalation study in which increasing doses of CD4 T cells targeting an antigen found on melanoma cells are given at three different levels. Outcome measures for this study include toxicity, T cell survival after infusion, tumor shrinkage, and loss of targeted antigen expression by the tumor after T cell infusion.